Back to top
more

AMAG Pharmaceuticals, Inc. (AMAG)

(Real Time Quote from BATS)

$11.10 USD

11.10
74,248

+0.39 (3.64%)

Updated Dec 6, 2019 11:05 AM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | D Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for AMAG

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for AMAG Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 394 329 579 466 144
Receivables 75 104 92 86 43
Notes Receivable 10 0 0 0 0
Inventories 27 37 37 41 41
Other Current Assets 19 12 10 14 47
Total Current Assets 525 482 719 607 274
Net Property & Equipment 8 26 24 29 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1 0 0 0 0
Intangibles 640 1,344 1,732 1,836 1,094
Deposits & Other Assets 2 1 4 16 20
Total Assets 1,175 1,853 2,478 2,487 1,389
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 21 0 0 0 0
Accounts Payable 14 10 4 5 7
Current Portion Long-Term Debt 0 0 21 18 34
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 130 175 156 106 81
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 92 132 117 44
Total Current Liabilities 165 278 313 246 166
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 48 212 194 78
Convertible Debt 262 268 179 174 167
Long-Term Debt 0 466 786 811 294
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 2 54 129 224
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 429 1,063 1,544 1,555 929
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,293 1,272 1,238 1,234 794
Retained Earnings -542 -478 -300 -298 -330
Other Equity -4 -4 -4 -4 -4
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 747 790 934 932 460
Total Liabilities & Shareholder's Equity 1,175 1,853 2,478 2,487 1,389
Total Common Equity 747 790 934 932 460
Shares Outstanding 34.50 35.30 34.20 34.70 25.30
Book Value Per Share 21.64 22.39 27.32 26.87 18.18

Fiscal Year End for AMAG Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Assets          
Cash & Equivalents 192 261 267 394 428
Receivables 78 83 83 75 85
Notes Receivable 0 0 0 10 0
Inventories 29 25 30 27 28
Other Current Assets 43 25 41 19 13
Total Current Assets 341 394 420 525 554
Net Property & Equipment 8 8 9 8 7
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1 1 1 1 1
Intangibles 610 614 636 640 653
Deposits & Other Assets 7 7 8 2 1
Total Assets 967 1,024 1,073 1,175 1,216
Liabilities & Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Notes Payable 0 0 0 21 21
Accounts Payable 27 27 22 14 30
Current Portion Long-Term Debt 4 4 4 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 172 214 156 130 142
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 1 2 0 0
Total Current Liabilities 204 246 183 165 193
Mortgages 0 0 0 0 0
Deferred Taxes/Income 5 5 4 0 0
Convertible Debt 273 269 266 262 258
Long-Term Debt 3 4 4 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 1 1 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 486 525 458 429 454
Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,292 1,288 1,282 1,293 1,286
Retained Earnings -809 -785 -665 -542 -520
Other Equity -3 -3 -3 -4 -4
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 481 500 615 747 762
Total Liabilities & Shareholder's Equity 967 1,024 1,073 1,175 1,216
Total Common Equity 481 500 615 747 762
Shares Outstanding 33.90 33.70 33.70 34.50 34.50
Book Value Per Share 14.18 14.82 18.24 21.64 22.09